AU2001275438A1 - Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof - Google Patents

Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof

Info

Publication number
AU2001275438A1
AU2001275438A1 AU2001275438A AU7543801A AU2001275438A1 AU 2001275438 A1 AU2001275438 A1 AU 2001275438A1 AU 2001275438 A AU2001275438 A AU 2001275438A AU 7543801 A AU7543801 A AU 7543801A AU 2001275438 A1 AU2001275438 A1 AU 2001275438A1
Authority
AU
Australia
Prior art keywords
proteins
fixed
viral capsid
stable
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001275438A
Other languages
English (en)
Inventor
Robert Garcea
C. Richard Schlegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of AU2001275438A1 publication Critical patent/AU2001275438A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001275438A 2000-07-06 2001-06-11 Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof Abandoned AU2001275438A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21652600P 2000-07-06 2000-07-06
US60/216,526 2000-07-06
PCT/US2001/018701 WO2002004007A2 (fr) 2000-07-06 2001-06-11 Formes (fixes) stables de proteines virales capsidiales et de proteines virales capsidiales hybrides, de preference les proteines l1 du papillomavirus, et leurs utilisations

Publications (1)

Publication Number Publication Date
AU2001275438A1 true AU2001275438A1 (en) 2002-01-21

Family

ID=22807390

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001275438A Abandoned AU2001275438A1 (en) 2000-07-06 2001-06-11 Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof

Country Status (7)

Country Link
US (1) US7279306B2 (fr)
EP (1) EP1305039B1 (fr)
AT (1) ATE418997T1 (fr)
AU (1) AU2001275438A1 (fr)
DE (1) DE60137230D1 (fr)
ES (1) ES2317910T3 (fr)
WO (1) WO2002004007A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
EP2272525A3 (fr) 2002-07-05 2011-11-16 Folia Biotech Inc. Particule virale adjuvante
EP1784145B1 (fr) 2004-08-30 2011-08-10 Neville Alleyne Implant pour traiter des ligaments et des tendons
JP2008511420A (ja) 2004-08-30 2008-04-17 スピネオベイションズ・インコポレーテッド 脊髄の椎間板内障害の治療の方法
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
AT503690A1 (de) 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
US8778351B2 (en) 2006-08-30 2014-07-15 University Of Rochester Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
US8916342B2 (en) 2006-11-13 2014-12-23 Oncohealth Corp. Identification of high grade or ≧ CIN2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (HPV) and HPV-associated cancers
US8968995B2 (en) 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US20100003704A1 (en) 2008-06-13 2010-01-07 Shuling Cheng IN SITU detection of early stages and late stages HPV infection
EP2078086A4 (fr) 2006-11-15 2010-06-30 Folia Biotech Inc Systèmes d'antigène conjugué par affinité immunogène fondés sur le virus de la mosaïque de la papaye et utilisation de ceux-ci
CA2703066A1 (fr) * 2007-10-22 2009-04-30 University Of Rochester Vaccin contre le virus syncytial respiratoire base sur des capsomeres ou des particules chimeriques semblables au virus du papillomavirus
US8469961B2 (en) 2008-03-05 2013-06-25 Neville Alleyne Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints
WO2010045431A2 (fr) * 2008-10-17 2010-04-22 The Regents Of The University Of Colorado, A Body Corporate Formulations de poudres sèches, vaccins et procédés
EP2521914A4 (fr) 2010-01-08 2013-07-10 Oncohealth Corp Immunoessais sur le vph à base de cellule et à haut débit pour diagnostiquer et dépister des cancers associés au vph
CN111000991B (zh) * 2019-12-20 2023-04-21 浙江普康生物技术股份有限公司 柯萨奇病毒a组6型重组亚单位蛋白疫苗及其制备方法
CN112472821B (zh) * 2020-11-19 2022-11-18 北京大学 一种蛋白质纳米颗粒用于制备抗vsv病毒产品的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US5475099A (en) * 1990-08-15 1995-12-12 Calgene Inc. Plant fatty acid synthases
US6071716A (en) * 1990-10-01 2000-06-06 Dana-Farber Cancer Institute DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
GB2279651A (en) * 1993-07-01 1995-01-11 British Tech Group Synthetic peptides of human papillomavirus
US6130316A (en) * 1993-07-26 2000-10-10 Dana Farber Cancer Institute Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
US5942607A (en) * 1993-07-26 1999-08-24 Dana-Farber Cancer Institute B7-2: a CTLA4/CD28 ligand
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
GB9420146D0 (en) * 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
CA2202090C (fr) * 1994-10-07 2012-04-17 Lutz Gissmann Particules semblables au virus du papillome, proteines de fusion et leur procede de production
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US5874089A (en) * 1995-10-02 1999-02-23 Georgetown University School Of Medicine Protecting against canine oral papillomavirus (copy)
ES2268787T3 (es) * 1997-09-05 2007-03-16 Medimmune, Inc. Metodo in vitro de desmontaje/embalaje de particulas similares a virus (vlp) de papilomavirus.
WO2000050447A1 (fr) * 1999-02-24 2000-08-31 Acorda Therapeutics Peptides mimetiques d'epitope glucidique et utilisations correspondantes
US6551597B1 (en) * 1999-03-18 2003-04-22 President & Fellows Of Harvard College Vaccine compositions for human papillomavirus
DE19925199A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie

Also Published As

Publication number Publication date
ES2317910T3 (es) 2009-05-01
US7279306B2 (en) 2007-10-09
WO2002004007A3 (fr) 2002-04-18
US20070212374A1 (en) 2007-09-13
WO2002004007A9 (fr) 2002-10-10
EP1305039A2 (fr) 2003-05-02
DE60137230D1 (de) 2009-02-12
ATE418997T1 (de) 2009-01-15
WO2002004007A2 (fr) 2002-01-17
EP1305039B1 (fr) 2008-12-31

Similar Documents

Publication Publication Date Title
AU2001275438A1 (en) Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
TR200001842T2 (tr) Papilloma virüs kapsomer aşı formülasyonları- kullanım metotları.
DE69535018D1 (de) Papillomavirus vakzine
PT1526172E (pt) Processo para a replicação de vírus influenza em cultura celular e os vírus influenza que podem ser obtidos pelo processo
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
AU2001236042A1 (en) Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
AU7545801A (en) Chimeric human papillomavirus (hpv) l1 molecules and uses therefor
UA85536C2 (en) Viral antigens
DE60037450D1 (de) Funf-helix protein
MXPA02007478A (es) Vacuna contra el virus de inmunodeficiencia humana.
AU2002228650A1 (en) Gas dehydration using membrane and potassium formate solution
WO2004101598A3 (fr) Insertion de sites de clivage de furine protease dans des proteines de membrane et leurs utilisations
TW200505501A (en) CCI-779 lyophilized formulations
AU5137800A (en) Cd4-independent hiv envelope proteins as vaccines and therapeutics
CY1107431T1 (el) Σωματιδια για γoνιδιακη θεραπεια
MXPA02012593A (es) Particulas de tipo virus del virus de la diarrea viral bovina.
EP0957936A4 (fr) Formulations de vaccins a base de papillonavirus recombine
AU5460900A (en) Infectious cdna clone of gb virus b and uses thereof
MXPA02003328A (es) Vacuna.
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
EP1309342A4 (fr) Production de papillomavirus humain chimerique
AP1561A (en) Use of non-cytolytic retrovirus as vaccines for the treatment of HIV infection.
AU4088299A (en) Novel post-transcriptional regulatory elements and uses thereof
DE69728447D1 (de) Veränderte, kleine rna-viren
WO2000005347A3 (fr) Systeme de culture de l'hepatite b